How big is Tandem Diabetes Care, Inc.?

As of Jun 18, Tandem Diabetes Care, Inc. has a market capitalization of $1.34 billion, with net sales of $982.95 million and a net profit of -$183.86 million over the latest four quarters. Shareholder's funds are $263.10 million, and total assets amount to $967.66 million.

As of Jun 18, Tandem Diabetes Care, Inc. has a market capitalization of 1,336.81 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 982.95 million for the latest four quarters, while the net profit for the same period was -183.86 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 263.10 million and total assets amounting to 967.66 million.

What does Tandem Diabetes Care, Inc. do?

Tandem Diabetes Care, Inc. is a medical device company that designs and commercializes products for insulin-dependent diabetes. As of March 2025, it reported net sales of $234 million and a net loss of $131 million, with a market cap of approximately $1.34 billion.

Overview: <BR>Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing, and commercialization of products for people with insulin-dependent diabetes, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 234 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -131 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,336.81 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.01 <BR>Return on Equity: -69.96% <BR>Price to Book: 8.61<BR><BR>Contact Details: <BR>Address: 11075 Roselle St, SAN DIEGO CA: 92121-1204 <BR>Tel: 1 858 3666900 <BR>Website: https://www.tandemdiabetes.com/

Should I buy, sell or hold Tandem Diabetes Care, Inc.?

Who are in the management team of Tandem Diabetes Care, Inc.?

As of March 2022, the management team of Tandem Diabetes Care, Inc. includes Chairman Kim Blickenstaff, CEO John Sheridan, Lead Independent Director Dick Allen, and Independent Directors Rajwant Sodhi, Edward Cahill, Peyton Howell, and Kathleen McGroddy-Goetz. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Tandem Diabetes Care, Inc. includes the following individuals:<BR><BR>- Mr. Kim Blickenstaff, Chairman of the Board<BR>- Mr. John Sheridan, President, Chief Executive Officer, and Director<BR>- Mr. Dick Allen, Lead Independent Director<BR>- Mr. Rajwant Sodhi, Director<BR>- Mr. Edward Cahill, Independent Director<BR>- Ms. Peyton Howell, Independent Director<BR>- Ms. Kathleen McGroddy-Goetz, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Tandem Diabetes Care, Inc. overvalued or undervalued?

As of August 3, 2022, Tandem Diabetes Care, Inc. is considered overvalued and risky due to its negative P/E ratio, poor return metrics, and significant underperformance compared to the S&P 500, indicating operational challenges and a weaker valuation relative to peers.

As of 3 August 2022, Tandem Diabetes Care, Inc. moved from a fair to risky valuation grade, indicating a deterioration in its investment appeal. The company appears to be overvalued, particularly given its negative P/E ratio and poor return metrics, with a Price to Book Value of 8.91 and an EV to Sales ratio of 1.41. Additionally, the latest ROCE and ROE stand at -65.75% and -69.96%, respectively, highlighting significant operational challenges.<BR><BR>In comparison to its peers, Tandem's valuation is notably weaker, with TransMedics Group, Inc. trading at a fair valuation with a P/E of 50.23, while Integer Holdings Corp. is categorized as very expensive with a P/E of 41.17. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -63.24% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued in its current state.

Is Tandem Diabetes Care, Inc. technically bullish or bearish?

As of October 3, 2025, Tandem Diabetes Care, Inc. shows a mildly bearish technical trend, with mixed MACD signals and recent outperformance against the S&P 500, but significant negative long-term returns of -58.33% year-to-date and -64.07% over the past year.

As of 3 October 2025, the technical trend for Tandem Diabetes Care, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD remains bearish. The daily moving averages are mildly bearish, and both the weekly and monthly Bollinger Bands are also mildly bearish. The KST and Dow Theory show bearish and mildly bearish signals respectively on the weekly and monthly time frames. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 27.31% and 19.32% compared to 1.09% and 4.15% for the index. However, the longer-term returns are significantly negative, with a year-to-date return of -58.33% and a one-year return of -64.07%, while the S&P 500 has gained 14.18% and 17.82% respectively. Overall, the current technical stance is mildly bearish.